NCT00392717|CompletedPhase 3
Regulation of Lipoprotein Metabolism in Obese Men
Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity
Loading search results
Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity
Sponsor study identifier
interventional
48
1 country
1
Study Start
February 1998
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
March 2002
Date type not reportedThis date has not been verified as actual or estimated.
Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS). Recent evidence has clearly established that the risk of CVD is increased in subjects with the MetS. The precise reason for this remains unclear, but appears to be closely related with dyslipidaemia. Effective management of dyslipidaemia is important to reduce the risk of CVD in these subjects. Hypothesis: Inhibition of hepatic cholesterol synthesis by statins and triglyceride synthesis by fish oils improve lipoprotein metabolism in visceral obese men.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2002
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1998
Date type not reportedThis date has not been verified as actual or estimated.
March 2002
Date type not reportedThis date has not been verified as actual or estimated.
October 25, 2006
Actual (reported)October 26, 2006
Actual (reported)Fractional catabolic rate of apoB, apoA, apoC-III and chylomicron remnants (before and after 6 week treatments)
Production rate of apoB, apoA, apoC-III and chylomicron remnants (before and after 6 week treatments)
Cholesterol
Triglyceride
LDL-cholesterol
Adipocytokines
Genetic polymorphisms
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Royal Perth Hospital
Perth, Western Australia, 6000, Australia
Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009 Mar;94(3):989-97. doi: 10.1210/jc.2008-1457. Epub 2008 Dec 30.
Dick C Chan, PhD
The University of Western Australia
Gerald F Watts, MBBS PhD
The University of Western Australia
P Hugh H Barrett, PhD
The University of Western Australia
First Submitted
October 25, 2006
First Posted
October 26, 2006
Study Start
February 1998
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
March 2002
Date type not reportedEuropean Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
October 26, 2006
Record last verified: 2006-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: